quadgram

This is a table of type quadgram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

quadgram	frequency
x x x x	98
x a x a	88
a x a x	80
acute respiratory distress syndrome	66
the study will be	58
will be used to	49
the end of the	46
in accordance with the	43
at the time of	37
be included in the	36
in patients with covid	35
chronic obstructive pulmonary disease	34
will be compared between	32
will be included in	32
study protocol for a	30
for the treatment of	30
will be used for	30
neutral with regard to	28
to jurisdictional claims in	28
nature remains neutral with	28
published maps and institutional	28
springer nature remains neutral	28
in published maps and	28
maps and institutional affiliations	28
remains neutral with regard	28
regard to jurisdictional claims	28
jurisdictional claims in published	28
claims in published maps	28
with regard to jurisdictional	28
in critically ill patients	27
in the control group	27
the trial will be	27
to participate in the	25
as well as the	25
a summary of the	24
the primary outcome is	24
acute hypoxic respiratory failure	24
the intensive care unit	24
and approved the final	24
of the full protocol	23
data will be collected	23
end of the study	23
note springer nature remains	23
summary of the key	22
accessible from the trials	22
is attached as an	22
the familiar formatting has	22
serves as a summary	22
letter serves as a	22
as part of the	22
familiar formatting has been	22
expediting dissemination of this	22
key elements of the	22
the proportion of patients	22
attached as an additional	22
of the key elements	22
as an additional file	22
as a summary of	22
dissemination of this material	22
this letter serves as	22
at the end of	22
formatting has been eliminated	22
the key elements of	22
elements of the full	22
from the trials website	22
be compared between the	22
patients will be randomized	22
in expediting dissemination of	21
any of the following	21
efficacy and safety of	21
interest in expediting dissemination	21
the interest in expediting	21
severe acute respiratory syndrome	21
in the case of	21
in the interest in	21
the control group will	20
be recorded in the	20
protocol is attached as	20
between the two groups	20
read and approved the	20
full protocol is attached	19
the full protocol is	19
accompanies this paper at	19
authors declare that they	19
they have no competing	19
have no competing interests	19
information accompanies this paper	19
systematic review and meta	19
will be asked to	19
supplementary information accompanies this	19
the authors declare that	19
declare that they have	19
that they have no	19
if the patient is	19
this paper at https	19
numbers to be randomised	18
one of the following	18
a study protocol for	18
inclusion and exclusion criteria	18
structured summary of a	18
of the study will	18
randomized to ravulizumab bsc	18
will be obtained from	18
approved the final manuscript	18
sudden sensorineural hearing loss	17
summary of a study	17
the use of the	17
this study will be	17
of a study protocol	17
a structured summary of	17
is based on the	17
in the treatment of	17
in the intensive care	17
informed consent will be	17
a randomised controlled trial	17
will be stored in	17
will be performed by	17
patients randomized to ravulizumab	17
compared with bsc alone	17
will be conducted in	17
the primary efficacy outcome	17
of this study is	17
analyses will be performed	16
will be carried out	16
the data will be	16
will be performed using	16
a systematic review and	16
study will be conducted	16
the efficacy and safety	16
the design of the	15
all data will be	15
from the corresponding author	15
protocol for a randomised	15
will be analyzed using	15
compared between the two	15
a total of patients	15
participate in the study	15
continuous positive airway pressure	15
time to clinical improvement	15
consent will be obtained	15
samples will be collected	15
will have access to	14
these events will be	14
sequential organ failure assessment	14
with the use of	14
as soon as possible	14
each of these events	14
of these events will	14
available from the corresponding	14
will be recorded in	14
the investigator or designee	14
authors read and approved	14
a randomized controlled trial	14
reduce the risk of	14
participation in the study	14
the course of the	14
the informed consent form	14
the corresponding author on	14
in the absence of	14
of the study is	14
the start of the	14
analysis of the primary	13
in patients with severe	13
will be followed up	13
no more than days	13
will be reported to	13
have access to the	13
the results of the	13
fraction of inspired oxygen	13
will be randomized to	13
at least one of	13
within the first h	13
of the study intervention	13
the discretion of the	13
least one of the	13
twice daily for days	13
all authors read and	13
has been shown to	13
data will be stored	13
of therapy and follow	12
of chronic obstructive pulmonary	12
in patients with acute	12
design of the study	12
completion of therapy and	12
will be performed in	12
will be presented as	12
corresponding author on reasonable	12
blood samples will be	12
included in the study	12
author on reasonable request	12
will have the option	12
in the intervention group	12
of the study and	12
randomised controlled trial date	12
the standard of care	12
peking university first hospital	12
for a randomised controlled	12
analysis will be conducted	12
the completion of therapy	12
the primary evaluation period	12
course of the study	12
criteria for adverse events	12
the study at any	12
a copy of the	12
patients admitted to the	12
the first days after	12
for the prevention of	12
during the study period	12
by the treating physician	12
will be reported as	12
the case report form	12
a sample size of	11
of the trial will	11
at the discretion of	11
be documented in the	11
duration of mechanical ventilation	11
the treatment of covid	11
the primary and secondary	11
adverse events will be	11
is defined as the	11
in the data analysis	11
will be performed at	11
any untoward medical occurrence	11
study if early intervention	11
secondary outcomes will be	11
events will be recorded	11
control group will receive	11
have the option to	11
analysis will be performed	11
if early intervention with	11
any time during the	11
to the use of	11
the ministry of health	11
and interpretation of data	11
critically ill patients with	11
related to the study	11
the primary outcome will	11
of the trial and	11
are available from the	11
d proportion of patients	11
be reported to the	11
the duration of the	11
common terminology criteria for	11
terminology criteria for adverse	11
will be performed on	11
proportion of patients with	11
this group will be	11
the inclusion and exclusion	10
the development of the	10
to severe respiratory failure	10
and institutional affiliations the	10
infants hospitalised with bronchiolitis	10
all analyses will be	10
to evaluate the effect	10
protocol for a randomized	10
fondation adolphe de rothschild	10
the standard protocol items	10
in this study will	10
a serious adverse event	10
to one of the	10
during the current study	10
is expected to be	10
subject will be included	10
the declaration of helsinki	10
body surface area once	10
according to the following	10
the patient will be	10
the acute respiratory distress	10
will be collected from	10
patients will be recruited	10
during the course of	10
will be collected at	10
to study if early	10
to the study drug	10
primary outcome will be	10
mg kg twice daily	10
in the active group	10
will be recruited from	10
la prise en charge	10
study at any time	10
the primary endpoint is	10
duration of the study	10
of the study protocol	10
to standard of care	10
patients with severe covid	10
surface area once daily	10
general data protection regulation	10
at any time during	10
will be recorded on	10
at baseline and at	10
patients in the active	10
ethics committee of the	10
the data monitoring committee	10
will be stratified by	10
evaluate the effect of	10
for the primary outcome	10
there will be no	10
this trial will be	10
the sample size calculation	10
will be blinded to	10
in addition to the	10
will be assessed by	10
in the design of	10
in the case report	9
m body surface area	9
the nature of the	9
the intervention and control	9
by the investigator or	9
will be analysed as	9
be followed up for	9
the conduct of the	9
will be randomly assigned	9
will be provided to	9
by the study team	9
after the completion of	9
will be made available	9
sargramostim mcg m body	9
will be provided by	9
is the proportion of	9
a reduction in the	9
until the end of	9
national institutes of health	9
in hospitalized patients with	9
it is estimated that	9
randomization will be performed	9
can be found in	9
be blinded to the	9
analyses will be conducted	9
in the first days	9
proportion of patients experiencing	9
the balance main trial	9
on day and day	9
regression will be used	9
included in the data	9
to the occurrence of	9
for more than hours	9
for the duration of	9
all saes will be	9
by the presence of	9
will be conducted at	9
mcg m body surface	9
is the responsibility of	9
is shown in fig	9
randomized controlled trial date	9
the responsibility of the	9
sartre study eudract number	9
ketamine will be discontinued	9
access to the full	9
the occurrence of each	9
will be collected for	9
the incidence of moderate	9
the statistical analysis plan	9
end of the trial	9
the last infusion of	9
will be collected and	9
will be published in	9
need for mechanical ventilation	9
during the screening period	9
in the event of	9
for patients randomized to	9
the rescue intervention strategy	9
by the research team	9
consent to participate in	9
acute lung injury and	9
at day and day	9
to ensure that the	9
the analysis of the	9
analysed as a binary	8
those who cannot take	8
x a x b	8
be analysed as a	8
be provided by the	8
will be done by	8
no role in the	8
in patients with ards	8
data will be presented	8
with acute respiratory distress	8
patients under critical care	8
the aim of this	8
des lavages de nez	8
be obtained from all	8
a x b x	8
will be assigned a	8
hospitalised patients with covid	8
proportion of patients who	8
in the delivery room	8
the participants will be	8
be performed by the	8
the current study are	8
of the following criteria	8
standard of care for	8
in patients who at	8
be obtained from the	8
proactive prophylaxis with azithromycin	8
the world health organization	8
as a binary outcome	8
part of the study	8
the implementation of the	8
page of alexion confidential	8
a retrospective cohort study	8
of cytokine release syndrome	8
participate in the trial	8
there is a large	8
will be submitted to	8
will be stored at	8
with acute lung injury	8
de patients ayant une	8
related quality of life	8
be submitted to the	8
institutional affiliations the authors	8
patients with acute stroke	8
group will have the	8
in the presence of	8
university of medical sciences	8
to the study intervention	8
by intubated or not	8
in healthcare workers with	8
cox proportional hazards model	8
the patient is not	8
will be compared using	8
of acute respiratory distress	8
middle east respiratory syndrome	8
de plus de points	8
of each of these	8
patients who at randomisation	8
be informed about the	8
the total number of	8
with a combination of	8
australia and new zealand	8
to the control group	8
a randomized clinical trial	8
of patients will be	8
mashhad university of medical	8
be randomly assigned to	8
primary outcome is the	8
electronic case report form	8
this study is to	8
prophylaxis with azithromycin and	8
use of the drug	8
the primary endpoint will	8
conduct of the study	8
to provide informed consent	8
on the other hand	8
with acute hypoxic respiratory	8
the relationship in time	8
at high risk of	8
intubated or not intubated	8
occurrence of each of	8
samples will be stored	8
or not intubated on	8
stratified by intubated or	8
recommendations for interventional trials	8
and safety monitoring board	8
pourcentage de patients ayant	8
for those who cannot	8
will be conducted as	8
will be screened for	8
the severity of the	8
has the potential to	8
as well as a	8
within days will be	8
acute respiratory syndrome coronavirus	8
once daily for days	8
not intubated on day	8
data and safety monitoring	8
there are currently no	8
who at randomisation were	8
trial will be conducted	8
primary and secondary outcomes	8
the patients will be	8
relationship to the study	8
for at least years	8
time to the occurrence	8
and institutional affiliations we	8
signs and symptoms of	8
an adverse event which	8
of the primary outcome	8
will be excluded from	8
it is the responsibility	8
data will be analyzed	8
will be informed about	8
not consistent with the	8
approved the final version	8
that the use of	7
pneumoniae and chlamydia species	7
the onset of symptoms	7
this is a prospective	7
will be provided with	7
investigator is responsible for	7
sensitivity analyses will include	7
study are available from	7
analyzed during the current	7
events will be analysed	7
idiopathic sudden sensorineural hearing	7
the option to receive	7
to prevent one of	7
for at least weeks	7
on the day of	7
in the crf ecrf	7
and the control group	7
the intervention group will	7
to be completed by	7
participation in the trial	7
of the clinical trial	7
associated with acute respiratory	7
discharge from the hospital	7
the trial steering committee	7
of the informed consent	7
an increased risk of	7
days will be assigned	7
days of iv sargramostim	7
we would like to	7
the primary analysis will	7
will be assigned the	7
the epidemiological impact of	7
on the basis of	7
is defined as any	7
to assess the efficacy	7
the participant will be	7
and out of hospital	7
conducted in accordance with	7
will be limited to	7
approval and consent to	7
patients who die within	7
in hospitalised patients with	7
completion of the study	7
be notified to the	7
be randomized to receive	7
cluster randomized controlled trial	7
or until hospital discharge	7
the alternative hypothesis is	7
within the past months	7
to renal failure requiring	7
plus soc for covid	7
at day will be	7
patients aged years or	7
respiratory distress syndrome in	7
been approved by the	7
as measured by the	7
based on the treating	7
in the study will	7
american society of hematology	7
the clinical recovery time	7
alternative hypothesis is that	7
for at least months	7
in the incidence of	7
primary analysis will be	7
death in patients with	7
for a period of	7
at the same time	7
will be defined as	7
admitted to the icu	7
sample size of patients	7
were involved in the	7
to severe acute respiratory	7
patients in the control	7
with bsc alone on	7
severity of which is	7
will be collected in	7
the procedure will be	7
on top of standard	7
in the first h	7
not be reported as	7
free days number of	7
of standard of care	7
the use of a	7
and no later than	7
will be presented for	7
informed about the study	7
the effect of ravulizumab	7
progression to renal failure	7
x b x c	7
quality of life in	7
length of icu stay	7
interim analysis is planned	7
the patient information sheet	7
will be used as	7
the safety of the	7
days number of days	7
will be presented by	7
be used to compare	7
p f ratio is	7
their legally acceptable representative	7
of patients admitted to	7
in patients under critical	7
patients aged or older	7
is not consistent with	7
for the management of	7
cluster randomised controlled trial	7
prevent one of the	7
ravulizumab will be administered	7
will be replaced by	7
and consent to participate	7
the local ethics committee	7
day compared with bsc	7
ethics approval and consent	7
the ae crf ecrf	7
is one of the	7
standard of care and	7
invasive mechanical ventilatory support	7
be recorded on the	7
for the development of	7
at least years of	7
who die within days	7
within the first days	7
intervention to prevent one	7
alive and out of	7
during the first days	7
the intervention will be	7
study will be performed	7
up visits will be	7
before the start of	7
aged years or older	7
as a result of	7
as part of a	7
the first h of	7
effect of iloprost on	7
to the intervention arm	7
involved in the study	7
or the control group	7
die within days will	7
be stored in a	7
the p f ratio	7
of the primary endpoint	7
first h of life	7
will be randomized in	7
jun page of alexion	7
for critically ill patients	7
in the live home	7
withdraw from the study	7
after the end of	7
to assess the effect	7
of the declaration of	7
between the intervention and	7
of the primary efficacy	7
and quality of life	7
top of standard of	7
progressing to severe respiratory	7
be assigned the value	7
renal failure requiring dialysis	7
high risk of sars	6
additional days of iv	6
for mortality of adult	6
is a large number	6
hypoxic respiratory failure to	6
confirmed by recent laboratory	6
of treatment success after	6
was approved by the	6
have a huge impact	6
the investigator is responsible	6
will be called group	6
of severe acute respiratory	6
twice daily for those	6
will be conducted on	6
with standard supportive care	6
discharged from the hospital	6
from the study at	6
of versus days of	6
will be based on	6
stored in a secure	6
wilcoxon rank sum test	6
and maximal increase in	6
be approved by the	6
when the patient is	6
patients randomised to the	6
outcome and as a	6
in the prep group	6
in the united states	6
of the icu units	6
evaluate differences in the	6
for the analysis of	6
group will receive an	6
be provided to the	6
icu admission or death	6
in the critical care	6
during the intervention period	6
of the primary evaluation	6
that are currently being	6
to study if treatment	6
of lost to follow	6
day intervention with sargramostim	6
and risk factors for	6
and acute respiratory distress	6
trial is funded by	6
for the use of	6
the trial master file	6
untoward medical occurrence that	6
patients will be included	6
the study has been	6
but not limited to	6
adult inpatients with covid	6
intervention with inhaled sargramostim	6
foreseeable overflow of the	6
all serious adverse events	6
at day compared with	6
will be left to	6
to give access to	6
during the completion of	6
will be approved by	6
day period is reached	6
will be generated by	6
the inclusion criteria are	6
the pao fio ratio	6
until the day period	6
least years of age	6
on the foreseeable overflow	6
of ravulizumab bsc compared	6
clinical course and risk	6
mortality of adult inpatients	6
serious adverse event on	6
patients will be enrolled	6
en lavage de nez	6
for the purpose of	6
or analyzed during the	6
or legally acceptable representative	6
peripheral capillary oxygen saturation	6
and as a time	6
hospitalized patients with covid	6
patients that are currently	6
be conducted at the	6
the primary endpoint of	6
will be in the	6
will be responsible for	6
to evaluate differences in	6
obtained from all participants	6
study data will be	6
plus de points au	6
indigenous infants hospitalised with	6
huge impact on the	6
be analyzed using a	6
event on or before	6
at a dose of	6
between day and day	6
receive an additional days	6
b x c x	6
early intervention with inhaled	6
will be administered intravenously	6
at least weeks after	6
studies have shown that	6
or their legally acceptable	6
in patients with sars	6
patients in the icu	6
be randomized in a	6
risk factors for mortality	6
the foreseeable overflow of	6
impact on the foreseeable	6
will be invited to	6
for at least days	6
acutely ill medical patients	6
in medical patients with	6
targeted indoor residual spraying	6
patients will be randomly	6
the number of days	6
study if treatment with	6
in the northern territory	6
summary of product characteristics	6
in the study design	6
after the onset of	6
current study are available	6
to receive an additional	6
overflow of the icu	6
the opinion of the	6
and will not be	6
points au score odoratest	6
we will use the	6
be collected at baseline	6
bsc compared with bsc	6
with the help of	6
primary and secondary endpoints	6
respiratory failure to ards	6
to assess the safety	6
the subject or legally	6
the national institutes of	6
if a patient is	6
to evaluate the efficacy	6
the study by the	6
maximal value and maximal	6
being hospitalized across the	6
patients will be asked	6
for ten days or	6
if treatment with sargramostim	6
of days within the	6
will be presented in	6
option to receive an	6
will be kept in	6
suspected unexpected serious adverse	6
are eligible for inclusion	6
large number of covid	6
below on minimal l	6
or before d proportion	6
be left to the	6
compared to standard of	6
infected patients that are	6
analysis and interpretation of	6
the study intervention or	6
signs of cytokine release	6
increase the risk of	6
subject or legally acceptable	6
the beginning of the	6
participation in this study	6
of which is not	6
for a randomized controlled	6
must be informed that	6
imv in patients who	6
within days of the	6
effect of ravulizumab bsc	6
to the administration of	6
a huge impact on	6
used to assess the	6
and designed the study	6
to the full protocol	6
version to be published	6
patients with acute hypoxic	6
the study should be	6
in elderly patients with	6
to the development of	6
before d proportion of	6
at randomisation were in	6
intermittent positive pressure ventilation	6
a large number of	6
specified in the soa	6
course and risk factors	6
we are conducting a	6
the study and the	6
weeks prior to randomization	6
median and interquartile range	6
first days after enrollment	6
will be calculated for	6
in patients treated with	6
by recent laboratory test	6
on or before d	6
experiencing a serious adverse	6
acute exacerbation of copd	6
associated with the use	6
the results of this	6
reduction in the incidence	6
factors for mortality of	6
as specified in the	6
the university of oxford	6
x c x x	6
assess the safety of	6
are currently being hospitalized	6
patients included in the	6
withdrawn from the study	6
the cure rct is	6
the administration of the	6
ravulizumab bsc compared with	6
daily for those who	6
to withdraw from the	6
in the treatment group	6
with the exception of	6
model will be used	6
will be done using	6
the vast majority of	6
the balance main rct	6
the day period is	6
included in the trial	6
pwds and their caregivers	6
for early breast cancer	6
provided with standard supportive	6
the study intervention and	6
to take part in	6
to the intensive care	6
patients in each group	6
medical ethics committee of	6
progressive patients in the	6
and days of enrolment	6
exacerbations of chronic obstructive	6
currently being hospitalized across	6
au cours de la	6
becoming aware of the	6
in adult patients with	6
the study physician will	6
analyses will be done	6
current standard of care	6
must be recorded in	6
primary endpoint will be	6
any hospitalization or all	6
adverse event on or	6
detailed statistical analysis plan	6
number of days within	6
the trial was registered	6
nasal continuous positive airway	6
participants will be recruited	6
de points au score	6
randomized controlled trial of	6
between d and d	6
who cannot take oral	6
as determined by the	6
will be determined by	6
value and maximal increase	6
a binary outcome and	6
which is not consistent	6
is anticipated to be	6
iv twice daily for	6
in the context of	6
with standard hygiene requirements	6
ards could have a	6
group will be called	6
patients enrolled in the	6
by the use of	6
of patients experiencing a	6
of lopinavir ritonavir and	6
will not be reported	6
based dose of ravulizumab	6
days within the first	6
the aim of the	6
of synbiotic supplementation on	6
as the date of	6
a cluster randomised controlled	6
recorded in the case	6
will be summarized by	6
might be due to	6
hospitalized across the globe	6
active group will have	6
categorical variables will be	6
at the university of	6
an ae or sae	6
eligibility criteria for the	6
a member of the	6
will be given to	6
assess the efficacy of	6
start of the study	6
an additional days of	6
patients experiencing a serious	6
intravenously following this posology	6
be due to the	6
of adult inpatients with	6
relationship in time is	6
on minimal l min	6
binary outcome and as	6
test will be used	6
could have a huge	6
the active group will	6
sharing is not applicable	6
mean and standard deviation	6
group and the control	5
will be calculated by	5
in mechanically ventilated patients	5
datasets were generated or	5
on the use of	5
of the following events	5
not related to the	5
free of mechanical ventilation	5
ascending part of the	5
biological specimens for genetic	5
patients do not receive	5
with numbers of patients	5
be informed that their	5
ketamine infusion as an	5
administration of the study	5
the primary objective is	5
for patients who are	5
fentanyl and or midazolam	5
there is an urgent	5
length of stay in	5
by the ministry of	5
the need for intubation	5
provide written informed consent	5
participants will be asked	5
enrolled in the trial	5
will be followed until	5
data will be used	5
of the intervention to	5
continued from previous page	5
when patients do not	5
parallel group randomised trials	5
and new zealand clinical	5
can be used as	5
hiruz ctu will submit	5
will be included as	5
of vestibular function tests	5
the conclusion of the	5
as defined by the	5
reduce the incidence of	5
in a cohort of	5
the current proposed protocol	5
australian institute of health	5
patient safety information card	5
over a period of	5
dietary quality and pa	5
give access to the	5
at the level of	5
in the experimental group	5
enrollment when patients do	5
sargramostim will be replaced	5
will be no shortage	5
involved in the design	5
and the presence of	5
which a significant portion	5
study participants will be	5
in the setting of	5
ctu will submit to	5
of care in the	5
samples will be drawn	5
early intervention with sargramostim	5
missing data will be	5
the treatment of ards	5
as well as for	5
reduce the need for	5
or molecular analysis in	5
the applicable product information	5
within the last days	5
the decision to submit	5
is responsible for the	5
chez les patients covid	5
to the berlin definition	5
but are not limited	5
lopinavir ritonavir and interferon	5
are not limited to	5
major clinically relevant bleeding	5
current ascending part of	5
copd gold c d	5
consistent with the applicable	5
last infusion of study	5
the secondary outcomes include	5
for the presence of	5
trial was registered on	5
vous aviez avant le	5
of venous thromboembolism in	5
hospital of fudan university	5
during the procedure will	5
total sample size is	5
role in the design	5
part of the epidemiology	5
of the clinical study	5
access to the final	5
in collaboration with the	5
of critically ill patients	5
days of antibiotic treatment	5
the total duration of	5
prise en charge de	5
important protocol amendments to	5
in severe trauma patients	5
liver and kidney function	5
to the study team	5
be administered intravenously following	5
h ketamine will be	5
azithromycin and chloroquine in	5
the number of patients	5
in the source documents	5
in view of the	5
under severe air pollution	5
later than calendar days	5
be in accordance with	5
standard of care alone	5
proportion of patients progressing	5
be no shortage of	5
deviations from the protocol	5
preventing the fatal consequences	5
will be administered on	5
in patients in the	5
this is a single	5
has been used for	5
according to the berlin	5
shortage of patients that	5
applicable to this article	5
replaced by intravenous sargramostim	5
presence of elevated il	5
obtained from the subject	5
as the primary outcome	5
low birth weight infants	5
amendments to relevant parties	5
registry of clinical trials	5
plans to give access	5
and or fentanyl and	5
genetic or molecular analysis	5
requiring dialysis at day	5
no shortage of patients	5
of this intervention is	5
risk of asthma exacerbations	5
the fatal consequences of	5
part of a clinical	5
updated guidelines for reporting	5
the health of the	5
due to the nature	5
the medical ethics committee	5
patients admitted to hospital	5
cancer specialists and gps	5
the trial has been	5
with sarilumab at the	5
the same doses and	5
the progression from manageable	5
at the study center	5
conceived and designed the	5
alexion within hours of	5
will be asked for	5
adult patients admitted to	5
and chloroquine in hospitalised	5
department of health and	5
will also be reported	5
will be required to	5
on the management of	5
and rising since last	5
reported to the sponsor	5
and chronic health evaluation	5
risk factors associated with	5
in the event that	5
blinded to group assignment	5
mg orally twice daily	5
plans for communicating important	5
of the university hospital	5
patients with confirmed covid	5
in the evidence of	5
trial of versus days	5
will be protected by	5
ghent university hospital has	5
within the day period	5
the protocol will be	5
will be considered as	5
with inhaled sargramostim affects	5
this study aims to	5
results of the study	5
need for intubation and	5
plot will be presented	5
patients have completed the	5
elderly patients with acute	5
will receive mg ravulizumab	5
like to acknowledge the	5
in the proportion of	5
for the following variables	5
the final version of	5
bubonic or pneumonic plague	5
and death in patients	5
by the principal investigator	5
consent will be taken	5
to assess the impact	5
whether the patient has	5
showing more than organ	5
new zealand clinical trials	5
admitted to the hospital	5
do not receive of	5
or fentanyl and or	5
than days after the	5
in the definition of	5
patients progressing to severe	5
nasal intermittent positive pressure	5
hypoxic respiratory failure and	5
be discussed with the	5
be carried out in	5
used in clinical practice	5
the mean number of	5
up to mg kg	5
admitted to one of	5
acceptable representative will be	5
in the opinion of	5
inhaled sargramostim will be	5
notified to the sponsor	5
than or equal to	5
as part of routine	5
with azithromycin and chloroquine	5
statistical analyses will be	5
is not applicable to	5
that given the current	5
results of this study	5
ward at ghent university	5
and days of randomization	5
of a clinical study	5
the risk of asthma	5
will be randomized using	5
to the nature of	5
for up to days	5
in the management of	5
all participants will be	5
patients with acute respiratory	5
included in this study	5
analysis in this trial	5
and trial steering committee	5
composition of the data	5
will be evaluated by	5
chronic suppurative lung disease	5
and reporting structure a	5
with the standard protocol	5
be performed at the	5
data will be available	5
total and free c	5
the first year of	5
physiology and chronic health	5
respiratory and multi organ	5
patients will receive mg	5
between the specialist cancer	5
no datasets were generated	5
reported as an ae	5
is not related to	5
of peripheral vestibular function	5
will be used in	5
for the current proposed	5
certainty in the evidence	5
numbers of patients rising	5
consolidated standards of reporting	5
on the role of	5
a legally acceptable representative	5
will be randomly allocated	5
data safety monitoring board	5
guidelines for reporting parallel	5
the required sample size	5
entre les deux bras	5
randomization will be stratified	5
at the beginning of	5
relating to the study	5
for genetic or molecular	5
discretion of the treating	5
x b x x	5
to submit the report	5
clinical recovery time of	5
use of the study	5
be collected at the	5
the ethics committee of	5
time during the study	5
safety outcomes will be	5
single mg sarilumab dose	5
the first h after	5
data sharing is not	5
hospital has admitted confirmed	5
of mashhad university of	5
standard of care in	5
provided in the study	5
experimental and control groups	5
molecular analysis in this	5
heart failure nyha iii	5
submit the report for	5
procedure will be compared	5
defined by the presence	5
to initiate iv sargramostim	5
final version of the	5
min after the injection	5
minimal l min o	5
is to assess the	5
all patients will be	5
containing mg sarilumab in	5
data safety and monitoring	5
groups will be compared	5
dental pulp stem cells	5
reporting parallel group randomised	5
will be performed for	5
of the eminent intervention	5
of patients progressing to	5
will be maintained by	5
for preventing the fatal	5
nature or severity of	5
will be calculated using	5
to the central ec	5
with a deviated septum	5
consist of the following	5
intervention and control groups	5
b x x x	5
has admitted confirmed cases	5
partial pressure of oxygen	5
given the current ascending	5
evaluate the efficacy and	5
of the epidemiology curve	5
to the study design	5
patients or their legally	5
and for at least	5
will be filled out	5
chloroquine in hospitalised patients	5
to the control arm	5
for indoor residual spraying	5
will be sent to	5
days after enrollment when	5
the primary outcome measure	5
secondary endpoints will be	5
with respect to the	5
legally acceptable representative will	5
when all patients have	5
with dementia and their	5
be replaced by intravenous	5
patients will be followed	5
will be allocated to	5
administered intravenously following this	5
the k th stage	5
written informed consent will	5
upon progression of disease	5
for reporting parallel group	5
infusion of study drug	5
more than organ failure	5
the role of the	5
the common terminology criteria	5
outcomes in patients with	5
at d proportion of	5
and statistical code c	5
rising since last h	5
institute of health and	5
the international conference on	5
study physician at each	5
the local principal investigator	5
in this trial future	5
of which a significant	5
prep group compared to	5
no treatments directed at	5
day for all patients	5
admission to the icu	5
by the ethics committee	5
randomised controlled trial of	5
interim analysis will be	5
believe that given the	5
the nature or severity	5
of the interim analysis	5
in terms of the	5
blood sample will be	5
que vous aviez avant	5
the data protection act	5
therefore believe that given	5
the outcome of the	5
as defined in section	5
patients with coronavirus disease	5
associated with complement activation	5
storage of biological specimens	5
to ards could have	5
be rescued with sarilumab	5
identifying information will be	5
propofol and or fentanyl	5
support within the day	5
versus days of antibiotic	5
in the ae crf	5
severe acute respiratory distress	5
and multi organ failure	5
after enrollment when patients	5
will be documented in	5
will also be performed	5
sarilumab at the same	5
be performed in the	5
the objectives of the	5
withdraw from the trial	5
meier plot will be	5
will be performed according	5
while breathing room air	5
in acutely ill medical	5
of patients with covid	5
a combination of lopinavir	5
is supported by a	5
la fondation adolphe de	5
of the data monitoring	5
this is an open	5
the report for publication	5
communicating important protocol amendments	5
area once daily for	5
the difference between the	5
statistical analysis plan for	5
the feasibility of the	5
this trial future use	5
first days after stroke	5
patients infected with covid	5
and recruitment is ongoing	5
not applicable to this	5
the cure rct will	5
university hospital has admitted	5
of prep with hydroxychloroquine	5
the sponsor is responsible	5
of the study as	5
of biological specimens for	5
failure requiring dialysis at	5
are currently no treatments	5
will not be possible	5
study is to evaluate	5
treatment with ravulizumab bsc	5
of bronchiolitis in indigenous	5
indicated in the soa	5
may be due to	5
causal relationship to the	5
the study physician at	5
of health and welfare	5
as there is no	5
currently no treatments directed	5
at the same doses	5
will be able to	5
be found in the	5
from the time of	5
a positive test for	5
impliquant la personne humaine	5
in the reference group	5
participated in its design	5
physician at each site	5
we therefore believe that	5
enrolled in the study	5
that treatment with ravulizumab	5
is to evaluate the	5
changes to the protocol	5
sodium chloride for a	5
effects of iloprost on	5
meet the criteria for	5
will be stored for	5
criteria for the current	5
specimens for genetic or	5
protocol amendments to relevant	5
acute physiology and chronic	5
reliability of ctcae ratings	5
patients that are eligible	5
the prep group compared	5
the main secondary outcome	5
will continue to be	5
is discharged from the	5
rescued with sarilumab at	5
at ghent university hospital	5
last infusion of ravulizumab	5
on the same day	5
for communicating important protocol	5
the investigator will be	5
will be considered to	5
the current ascending part	5
and storage of biological	5
is defined as a	5
in writing the manuscript	5
the sample size and	5
approved by the ethics	5
the sponsor and the	5
or severity of which	5
the study design and	5
days free of mechanical	5
kidney and liver function	5
in just days time	5
data will also be	5
days alive and out	5
and drafted the manuscript	5
primary endpoint is the	5
patients who meet the	5
resource utilization in dementia	5
in ventilated trauma patients	5
saturation below on minimal	5
is that treatment with	5
hypothesis is that treatment	5
olfactives que vous aviez	5
will consist of the	5
in the trial will	5
low certainty in the	5
the risk of developing	5
methylprednisolone mg kg day	5
the effects of iloprost	5
be given to the	5
be sent to the	5
kg twice daily for	5
no later than calendar	5
in the study and	5
primary objective is to	5
as no datasets were	5
ent hospital of fudan	5
aim of this study	5
assess the impact of	5
eligible patients will be	5
fatal consequences of acute	5
be asked to sign	5
will be measured by	5
with ravulizumab bsc will	5
of patients rising sharply	5
will submit to the	5
patients showing more than	5
of patients that are	5
is an urgent need	5
of patients who are	5
with the applicable product	5
results will be reported	5
of the research team	5
of the intervention will	4
based on the results	4
air pollution monitoring station	4
will be recorded and	4
arterial blood gas determination	4
as described in the	4
in the study database	4
decision to submit the	4
functional assessment of cancer	4
guidelines for management of	4
prior to initiating ravulizumab	4
against placebo in healthcare	4
area once daily until	4
change from baseline in	4
or invasive mechanical ventilation	4
lavage de nez sera	4
in addition to these	4
accordance with the standard	4
are described in the	4
for inclusion in the	4
stored samples will be	4
be administered on day	4
event which might be	4
part of the trial	4
signature of the informed	4
to handle missing data	4
we anticipate that the	4
involved in data collection	4
and the use of	4
in the study at	4
will be transferred to	4
released to the participating	4
the timepoints indicated in	4
receiving satisfying responses to	4
the proposed intervention is	4
and safety of sarilumab	4
in two consecutive blood	4
statistical analysis will be	4
the patients in the	4
that may affect the	4
the relative stress scale	4
of asthma exacerbations per	4
an electronic randomization will	4
all patients who are	4
be screened for eligibility	4
premature termination of the	4
the presence of any	4
will be released to	4
option to initiate iv	4
the patient safety information	4
of the clinical team	4
used as part of	4
with blinded outcome assessment	4
of days free of	4
ray and or ct	4
and exclusion criteria are	4
data will be checked	4
les patients du groupe	4
practice in the live	4
in analysis to handle	4
a final concentration of	4
in severe acute respiratory	4
presence or absence of	4
asking questions and receiving	4
for measuring blood cytokine	4
the miracle trial is	4
receive jwby formulas plus	4
institutional affiliations we would	4
the data safety and	4
is defined as an	4
the risk of non	4
on how to administer	4
the patient information and	4
the institutional review board	4
described in this protocol	4
a total of subjects	4
in practice in the	4
censored in the case	4
the purpose of this	4
stable chronic obstructive pulmonary	4
new zealand clinical trial	4
have been approved by	4
included in an open	4
ravulizumab for patients randomized	4
is in the best	4
will occur in the	4
be released to the	4
a detailed description of	4
the ovid study will	4
be used to identify	4
of septoplasty versus medical	4
and is expected to	4
the type i error	4
are enrolled in the	4
been shown to reduce	4
the study was approved	4
once daily until the	4
hospital and research center	4
of bronchiectasis exacerbations in	4
kg iv twice daily	4
has been approved by	4
the total sample size	4
responses to all questions	4
clinical presentation consistent with	4
standard of care treatment	4
the patient is discharged	4
the exception of the	4
will be assessed using	4
in patients with a	4
adult respiratory distress syndrome	4
a fourfold increase in	4
be used as a	4
fio fraction of inspired	4
reducing their risk of	4
entry to the study	4
would lead to improved	4
induced acute lung injury	4
at least months from	4
consent to participate will	4
anticipated to be completed	4
conclusion of the study	4
the use of budesonide	4
treating physician will have	4
and before entry to	4
healthcare workers with negative	4
collected for measuring blood	4
timepoints indicated in the	4
of unplanned outpatient visits	4
and activation of immune	4
the study is to	4
conduct of the trial	4
to versus days of	4
a significance level of	4
both treatment groups will	4
this is a hospital	4
of the effects of	4
within days of randomization	4
moderate to severe ards	4
start of the trial	4
logistic regression will be	4
in case of progression	4
an accompanying person from	4
used in this trial	4
trial will be published	4
a clinical presentation consistent	4
by a member of	4
be censored in the	4
approximately patients will be	4
pwd and the caregiver	4
be maintained by the	4
ketamine will be continued	4
study intervention caused the	4
will be analyzed as	4
all adult patients admitted	4
handle missing data c	4
best of our knowledge	4
for both types of	4
data safety monitoring committee	4
development and validation of	4
of the exclusion criteria	4
for patients randomized and	4
international conference on harmonisation	4
hospitals and two large	4
x x x b	4
in patients with dementia	4
assessment of cancer therapy	4
for management of venous	4
ratio of pao fio	4
with azithromycin and hydroxychloroquine	4
combination with the log	4
is considered to be	4
skills to support behaviour	4
a deviated nasal septum	4
analysis or interpretation of	4
to the protocol will	4
features of secondary haemophagocytic	4
the intervention clinician will	4
to the best of	4
be used in this	4
size calculation is based	4
deemed clinically appropriate by	4
antibiotic prophylaxis for at	4
endpoint is the proportion	4
as described in this	4
receive standard of care	4
fio and through measurement	4
global burden of disease	4
ards in patients with	4
china clinical course and	4
we will assess the	4
or mg kg iv	4
about the study by	4
primary endpoint of this	4
days or until hospital	4
model for breast cancer	4
of discharge from hospital	4
to treat patients with	4
by intravenous sargramostim mcg	4
be filed in the	4
should continue antibiotic prophylaxis	4
time to resolution of	4
test for two independent	4
and any statistical methods	4
be removed from the	4
with an endotracheal tube	4
quality of life group	4
the control group and	4
after treatment with the	4
single iv injection on	4
she will be considered	4
the safety and efficacy	4
is estimated to be	4
that a causal relationship	4
as a nebulized inhalation	4
endpoint of this intervention	4
termination of the trial	4
to considerer the trial	4
for breast cancer survivors	4
if the patient has	4
should be considered in	4
mg methylprednisolone or equivalent	4
and no exclusion criteria	4
period of mechanical ventilation	4
of respiratory exacerbations by	4
if the patient does	4
will be notified to	4
the case of a	4
measurement of the p	4
the quintet recruitment intervention	4
the primary end point	4
in this group will	4
will be recorded as	4
will be performed to	4
dose ketamine infusion as	4
visits will be conducted	4
having received sufficient time	4
all adverse events will	4
the entire study period	4
manageable acute hypoxic respiratory	4
and through measurement of	4
relationship between the study	4
which might be due	4
recorded on the ae	4
days of antibiotics for	4
patients who are randomized	4
defined as the date	4
in patients with copd	4
to an investigational medicinal	4
secondary outcomes include the	4
mg kg iv twice	4
french ministry of health	4
admitted to the intensive	4
the closest study center	4
is voluntary and that	4
to oral administration once	4
in reducing their risk	4
up in healthcare workers	4
after admission to the	4
an untoward medical occurrence	4
must use a condom	4
of ravulizumab for patients	4
should receive prophylactic antibiotics	4
medical occurrence in a	4
the coordinating principle investigator	4
standard of care has	4
and will be performed	4
white blood cell count	4
the summary of product	4
hydroxychloroquine against placebo in	4
ravulizumab bsc will improve	4
to any of the	4
according to french law	4
interpretation of data and	4
be collected for measuring	4
duration of icu stay	4
details of the study	4
to handle protocol non	4
prior to the day	4
puncture will be taken	4
confirmed diagnosis of sars	4
treatment effects will be	4
data will be handled	4
to support behaviour change	4
which is defined as	4
and diversity of respiratory	4
the application of a	4
within hours after becoming	4
is conducted in accordance	4
in which patients are	4
will be informed that	4
intervention group will receive	4
acute respiratory and multi	4
data will be entered	4
the time of submission	4
treatment with sargramostim affects	4
safety and efficacy of	4
in the balance main	4
control group will be	4
analysis to handle protocol	4
will be conducted when	4
kept for at least	4
blood gas determination via	4
with high risk of	4
treatment for patients with	4
sample size calculation is	4
statistical methods to handle	4
liver and kidney failure	4
a causal relationship between	4
rater reliability of ctcae	4
are provided in the	4
and whether the patient	4
primary end point is	4
be made available in	4
ministry of health and	4
zealand clinical trial registry	4
determine the effect of	4
of participants will be	4
signed and dated by	4
national institute for health	4
the findings of this	4
quality of life of	4
or other medical intervention	4
be recorded as an	4
of secondary outcomes will	4
study is conducted in	4
be stored at the	4
other treatment will be	4
inclusion in the study	4
to this article as	4
obstructive pulmonary disease in	4
in line with the	4
of chronic lung disease	4
after this explanation and	4
very low birth weight	4
in combination with the	4
efficacy of the use	4
iv injection on day	4
a cox proportional hazards	4
be conducted as a	4
the efficacy of the	4
they would like to	4
controlled trial is to	4
with moderate to severe	4
duration of the trial	4
main secondary outcome is	4
in the outpatient setting	4
once deemed clinically appropriate	4
as a random effect	4
vaccination cannot be confirmed	4
in case of a	4
an urgent need for	4
the definition of serious	4
icu length of stay	4
take part in the	4
saes if evaluated as	4
if evaluated as suspected	4
interim analysis of the	4
by the research nurse	4
to a maximum of	4
the details of the	4
in the early stages	4
presentation consistent with covid	4
ciprofloxacin mg kg twice	4
standards of reporting trials	4
workers with high risk	4
the start of randomization	4
at the timepoints indicated	4
skills to support health	4
the study intervention caused	4
ml of whole blood	4
the early stages of	4
will be collected during	4
intravenous sargramostim mcg m	4
due to the use	4
have no role in	4
the following events occurring	4
in the development of	4
red blood cell hb	4
will be obtained by	4
in its design and	4
the investigators will be	4
date of the first	4
information about the study	4
based on the following	4
trial steering committee d	4
of antibiotic treatment for	4
if vaccination cannot be	4
that the patient is	4
on behalf of the	4
to improve hypertension control	4
of secondary haemophagocytic lymphohistiocytosis	4
prognosis of vestibular dysfunction	4
should be recorded in	4
an arterial blood gas	4
determination via arterial puncture	4
of patients showing more	4
or corticosteroid dose equivalents	4
will be conducted using	4
included in the analysis	4
for no more than	4
the final version to	4
for two independent samples	4
study by the treating	4
treatment and for at	4
outcome of the pregnancy	4
study drug will be	4
the global burden of	4
the pwd and the	4
this intervention is measuring	4
as well as other	4
of good clinical practice	4
who clinical improvement ordinal	4
of mechanical ventilation at	4
to halt the progression	4
after initiation of ravulizumab	4
be assigned a unique	4
and or analyzed during	4
for a minimum of	4
progression to respiratory failure	4
care model for breast	4
study was approved by	4
for important intellectual content	4
to alexion within hours	4
that event meets criteria	4
inclusion of the first	4
total of patients will	4
communication skills to support	4
improve outcome in elderly	4
group and in the	4
the date of the	4
first h ketamine will	4
all other treatment will	4
it is important to	4
unexpected and drug related	4
before entry to the	4
to the kfsh rc	4
in blocks of unknown	4
ml of venous blood	4
measuring blood cytokine and	4
would like to acknowledge	4
during the study intervention	4
was registered on april	4
gas determination via arterial	4
will be taken at	4
institute for health research	4
will be expressed as	4
the source documents and	4
and the final allocation	4
the study team and	4
be identified by a	4
for a total of	4
current version of the	4
saudi food and drug	4
the principal investigators will	4
and approved by the	4
blood cytokine and chemokine	4
is measuring oxygenation after	4
anaesthesia with an endotracheal	4
patients in the intervention	4
serum blood sample x	4
sensorineural hearing loss the	4
be reviewed by the	4
to measure the effectiveness	4
be used for the	4
in addition to standard	4
as soon as the	4
group will receive the	4
they should continue antibiotic	4
methods in analysis to	4
the general data protection	4
of at least one	4
hospital length of stay	4
the treating physician will	4
effects of synbiotic supplementation	4
to evaluate the safety	4
control program in argentina	4
administration of study drug	4
septoplasty versus medical management	4
will be returned to	4
for the prevention and	4
of the last patient	4
of the sponsor and	4
lung injury and the	4
outcome analysis will be	4
and the ethics committee	4
to the intervention group	4
on the prevention of	4
will receive jwby formulas	4
is defined as follows	4
months prior to the	4
received approval from the	4
mic is determined for	4
the critical care setting	4
and the decision to	4
will be the first	4
pour les patients du	4
positive samples will be	4
proposed intervention is that	4
the target sample size	4
to the study protocol	4
according to local clinical	4
consequences of acute respiratory	4
participants will be randomized	4
general anaesthesia with an	4
administration once they are	4
meeting the inclusion criteria	4
is a hospital based	4
on day patients will	4
for all patients who	4
satisfying responses to all	4
informed consent was obtained	4
on invasive mechanical ventilation	4
of pao fio and	4
the use of study	4
any statistical methods to	4
of breast cancer survivors	4
and receiving satisfying responses	4
in relation to fio	4
an allocation ratio of	4
data will be recorded	4
he or she has	4
increase in antibody titre	4
exclusion criteria will be	4
recorded in the crf	4
recherche impliquant la personne	4
pao fio and through	4
the recommended dose of	4
reliability and validity of	4
will be administered enoxaparin	4
will be made by	4
lung injury induced by	4
composition of the coordinating	4
sign the informed consent	4
number of weeks during	4
latest version of the	4
outcome in elderly patients	4
the patient does not	4
australian new zealand clinical	4
mg kg every h	4
days after the onset	4
investigator or designee will	4
the results will be	4
when patients are vaccinated	4
the use of anti	4
be collected and processed	4
a high incidence of	4
infusion as an analgo	4
placebo in healthcare workers	4
healthcare workers with high	4
progression of disease requiring	4
bronchiectasis exacerbations in children	4
fatal saes if evaluated	4
sufficient time to considerer	4
patients will be censored	4
to stop the trial	4
collect peripheral blood serum	4
be conducted in the	4
trial with blinded outcome	4
subgroup analyses will be	4
safety profile of the	4
the fifth affiliated hospital	4
daily for days as	4
treatments directed at improving	4
research council of norway	4
is any untoward medical	4
will be done on	4
in children with bronchiectasis	4
days or until discharge	4
after no more than	4
at and weeks post	4
two large cantonal hospitals	4
must be documented on	4
whether or not considered	4
patients who received the	4
in the form of	4
of acute respiratory and	4
will receive the standard	4
and cd t cells	4
be excluded from the	4
on restoring lung homeostasis	4
during an epidemic period	4
adverse event which is	4
the database will be	4
or significant disability incapacity	4
patients with bubonic plague	4
of the end of	4
be performed at baseline	4
ravulizumab treatment and for	4
the patient has any	4
mechanical ventilatory support within	4
samples will be processed	4
first h after randomization	4
x x b x	4
least months from the	4
on the ordinal scale	4
with the data protection	4
a protocol for a	4
clinically appropriate by the	4
least weeks after meningococcal	4
collected as part of	4
received as part of	4
consent will be accepted	4
iv sargramostim mcg m	4
the secondary objectives are	4
treatment through assessment of	4
by the medical ethics	4
the completion of the	4
admitted to the covid	4
event meets criteria for	4
methods to handle missing	4
two groups of patients	4
blocks of unknown size	4
patients in this group	4
progression from manageable acute	4
the exclusion criteria are	4
continue antibiotic prophylaxis for	4
max mg per dose	4
at any time without	4
mechanical ventilation at day	4
principles of the declaration	4
conducted according to the	4
in a timely manner	4
taking care of covid	4
pharmaceuticals for human use	4
days as a nebulized	4
processing of personal data	4
after receiving full explanation	4
line or study center	4
activation of immune cells	4
unexpected serious adverse reaction	4
as an adjunct to	4
as this is a	4
considered related to the	4
the progression of the	4
outcome is time to	4
stored in accordance with	4
and standard treatment parallel	4
defined as the last	4
blinded to the treatment	4
presented in combination with	4
time to considerer the	4
the hypothesis that the	4
food and drug authority	4
quality of life and	4
will be identified by	4
standard treatment parallel control	4
partial pressure of arterial	4
participated in the study	4
point category ordinal scale	4
if received as part	4
numbers to be randomized	4
during the primary evaluation	4
analysis for the global	4
will be performed before	4
after completion of the	4
the latest version of	4
or she will be	4
day patients will receive	4
optional edta blood sample	4
a trial of versus	4
the outcomes will be	4
calculated from the onset	4
electronic randomization will be	4
indigenous infants with bronchiolitis	4
measuring oxygenation after days	4
a systematic analysis for	4
case of lost to	4
of patients infected with	4
a serious adverse reaction	4
blood will be collected	4
the primary outcome of	4
will be given in	4
may switch to oral	4
the nih program officer	4
to support health behaviour	4
be considered as a	4
will be censored in	4
to swallow or once	4
in indigenous australian infants	4
the study is conducted	4
at the baseline visit	4
of the principal investigator	4
will be performed after	4
to detect differences in	4
of acute lung injury	4
the first h ketamine	4
will continue to receive	4
assess the effect of	4
a data safety monitoring	4
time to next exacerbation	4
be used to calculate	4
recorded as an ae	4
date data from the	4
patients with bloodstream infection	4
proportion of patients showing	4
more than days after	4
effects will be presented	4
be collected from the	4
will be entered into	4
years or older with	4
writing of the report	4
the hypothesis of the	4
to improve outcome in	4
the primary analysis is	4
and two large cantonal	4
accompanying person from the	4
reported in accordance with	4
the danish medicines agency	4
an investigational medicinal product	4
appropriate by the treating	4
initiating ravulizumab treatment and	4
according to our local	4
sargramostim mcg twice daily	4
be presented in combination	4
this study will also	4
via arterial puncture will	4
the study protocol has	4
profile of the study	4
final version to be	4
the presence of a	4
be considered to have	4
hypothesis of the proposed	4
block size will be	4
of the study drugs	4
adherence and any statistical	4
the queen elizabeth hospital	4
the best of our	4
the glasgow coma scale	4
epidemiological impact of tirs	4
to protect the rights	4
two consecutive blood gas	4
if he or she	4
or once deemed clinically	4
women of childbearing potential	4
mmhg in two consecutive	4
there are no plans	4
the rest of the	4
cytokine and chemokine levels	4
admitted to specialized covid	4
for days as a	4
arterial puncture will be	4
had no role in	4
patients randomized to the	4
of the first patients	4
complications to improve outcome	4
diversity of respiratory viruses	4
for the global burden	4
they are able to	4
ambulatory patients aged or	4
to reduce the incidence	4
daily until the day	4
during the months of	4
mcg twice daily for	4
primary outcome is time	4
are able to swallow	4
bsc best supportive care	4
in a subject to	4
to initiating ravulizumab treatment	4
for people with dementia	4
support health behaviour change	4
or the use of	4
ventilation or high flow	4
management of venous thromboembolism	4
end of the primary	4
criteria for a susar	4
through measurement of the	4
the time of randomization	4
number of days free	4
we will include patients	4
different peep levels during	4
use of budesonide formoterol	4
willing to provide informed	4
and the consent form	4
jia wei bushen yiqi	4
fourfold increase in antibody	4
the remainder of the	4
once they are able	4
as a function of	4
has been reported in	4
affiliations we would like	4
the randomization will be	4
be analysed according to	4
informed consent to participate	4
treatment will be unchanged	4
information will be recorded	4
informed consent is obtained	4
that provides the imp	4
be offered to the	4
final allocation will be	4
months after treatment with	4
randomized to receive either	4
between the study intervention	4
oxygenation after days of	4
including but not limited	4
will be given the	4
blood sample x ml	4
mean difference in score	4
au score odoratest jours	4
addition to standard care	4
ten days or until	4
implementation of the intervention	4
reduce the morbidity of	4
documentation in hospital records	4
or discharge from the	4
asthma exacerbations per year	4
person from the same	4
detailed description of the	4
local clinical practice protocols	4
swallow or once deemed	4
the trial is designed	4
average red blood cell	4
he or she will	4
after days of inhaled	4
will have no role	4
the study consists of	4
affiliated hospital of sun	4
national institutional review board	4
using a t test	4
measurements of oxygen saturation	4
the risk of death	4
awareness that event meets	4
from manageable acute hypoxic	4
sided significance level of	4
and on day patients	4
will be recruited in	4
measure the effectiveness of	4
systematic analysis for the	4
performed according to the	4
about the study and	4
within days of enrolment	4
halt the progression from	4
the treatment group and	4
a part of the	4
we would need patients	4
the first dose of	4
or a fourfold increase	4
burden of disease study	4
is in line with	4
for days or until	4
study drugs will be	4
the patient and the	4
any combination of these	4
will be collected by	4
infection in reducing their	4
an alternative explanation is	4
is to test the	4
alone in patients with	4
the final allocation will	4
and development of the	4
not expected to survive	4
with hydroxychloroquine against placebo	4
acute generalized exanthematous pustulosis	4
followed by ciprofloxacin mg	4
dans la prise en	4
is the most common	4
days following awareness that	4
invasive or invasive mechanical	4
of complications to improve	4
explanation and before entry	4
physician will have the	4
will receive placebo plus	4
asked to sign icf	4
this explanation and before	4
to detect a difference	4
of the proposed intervention	4
will be eligible to	4
adjusting for the following	4
will ensure that the	4
of care for the	4
progression of the disease	4
initiate iv sargramostim mcg	4
respiratory exacerbations by day	4
patients will only be	4
will participate in the	4
the case of lost	4
the data from the	4
that the incidence of	4
of the primary and	4
an adverse event is	4
be assessed by the	4
adverse event which might	4
will be in accordance	4
following awareness that event	4
oral administration once they	4
the american society of	4
the option to initiate	4
be reported by the	4
from the same household	4
seroconversion or a fourfold	4
be in blocks of	4
for both treatment groups	4
will be constructed using	4
the patient should receive	4
randomized and standard treatment	4
of the use of	4
patients will be informed	4
clinical trial with blinded	4
the primary objective of	4
event in which the	4
be followed up by	4
be performed using sas	4
saes will be reported	4
clinical improvement ordinal score	4
prevention of complications to	4
combination of lopinavir ritonavir	4
questions and receiving satisfying	4
atorvastatin with conventional therapy	4
creatinine clearance ml min	4
during endoscopic retrograde cholangiopancreatography	4
from patients randomized to	4
will be in blocks	4
who consent to participate	4
in at least two	4
the progress of the	4
intervention is measuring oxygenation	4
of technical requirements for	4
for more than h	4
a dose of mg	4
and dated by the	4
reviewed and approved by	4
will be imputed using	4
hours after becoming aware	4
calendar days following awareness	4
data must be collected	4
in preterm infants with	4
of neutrophil extracellular traps	4
in randomised controlled trials	4
from the hospital or	4
lead to improved short	4
kg day in the	4
parameters x a x	4
the national cancer institute	4
group will be administered	4
will not be considered	4
sample will be taken	4
the dsmb will meet	4
will be regarded as	4
sponsor and principal investigator	4
patient should receive prophylactic	4
soc group without sarilumab	4
received sufficient time to	4
we will perform daily	4
to local clinical practice	4
prophylaxis for at least	4
than calendar days following	4
fifth affiliated hospital of	4
one of the most	4
able to swallow or	4
by means of the	4
performed at baseline and	4
baseline and at and	4
the study team will	4
of this trial will	4
by the local principal	4
is associated with covid	4
the day of the	4
all authors contributed to	4
ventilatory support within the	4
weeks after meningococcal vaccination	4
included in the fas	4
du code de la	4
may be associated with	4
persistent or significant disability	4
guardian next of kin	4
on a global scale	4
of the adverse event	4
will be offered the	4
after becoming aware of	4
of weeks during which	4
be included in an	4
be performed according to	4
be taken into account	4
patients with medical illnesses	4
after inclusion of the	4
the sponsor and principal	4
all patients have completed	4
have a causal relationship	4
will be reported in	4
if there is a	4
serious adverse event is	4
nature of the study	4
switch to oral administration	4
this is a multi	4
and no treatment that	4
be analyzed using the	4
number of aes saes	4
peripheral blood serum to	4
will take place in	4
from the onset of	4
every hours in the	4
the study is being	3
patients randomized in the	3
and compared using a	3
primary outcome of this	3
the incidence of bpd	3
and data usage has	3
number of desaturation events	3
intervention and control group	3
task is experienced by	3
a wide range of	3
participants or their legal	3
family environment or support	3
attempt to contact the	3
will be compared in	3
person visit if the	3
problems with diagnostic sensitivity	3
subjects will be recruited	3
agreed to participate in	3
failures are defined as	3
the incidence of symptomatic	3
assessing the efficacy of	3
with nasal obstruction associated	3
be used to measure	3
failure fulfilling criteria for	3
an event in which	3
in patients undergoing ercps	3
on ageing and health	3
data analysis will be	3
in the medical record	3
and the results of	3
collection in private rooms	3
the first infusion of	3
the new p f	3
the study will also	3
mechanically ventilated icu patients	3
component of the primary	3
can only be enrolled	3
assigned to the study	3
cov infection treated with	3
accordance with the data	3
any clinically relevant bleeding	3
standard hygiene requirements at	3
participating in this clinical	3
patient and public involvement	3
to reduce the morbidity	3
clinical utilisation of respiratory	3
how burdensome the task	3
and processed with adequate	3
and with highly suspect	3
versus standard of care	3
is approved by the	3
radiologist and pulmonary physician	3
optimum level of peep	3
causal relationship with the	3
or equivalent cs dose	3
of the coordinating centre	3
at the study site	3
the evaluation of the	3